Graft Failure Clinical Trial
Official title:
Terminal Graft Failure: A Combined Pathologic and Clinical Study
One of the risks associated with heart transplantation is failure of the graft. A graft is
where the new heart is attached to the original vessels in the body. Approximately 10% of
children suffer graft failure which, leads to heart failure and possible death. The problem
is that we do not know some of the causes of graft failure thus, it is difficult to diagnose
early and treat. Due to graft failure, lots of children are placed back on the transplant
list and receive another new heart.
In this study, we plan to perform a retrospective chart review looking to see if we can
correlate graft failure with a problem with the vessels called coronary allograft
vasculopathy or rejection. In order to do this, we will collect data from patient's charts
that have been diagnosed with graft failure and compare their clinical presentation/data to
pathology reports of the explanted hearts from these children. Explanted hearts are the old
transplanted hearts that are removed in order to put a new heart into the body. Explanted
hearts at our institution are always sent to pathology for analysis thus it will be quite
easy to perform this review.
The objectives are to describe the pathology findings from the examination of the explanted
heart and correlate them with clinical variables such as catheterization data.
Children's Healthcare of Atlanta performs approximately 12-15 heart transplants a year. To
date, there have been 19 re-transplantations for late graft failure at Children's. The
pathologic and clinical records of these 19 patients will be studied. All data collected
will be entered into a database for future analysis.
Data Collection
A retrospective review of standard pathology findings from the examination of the explanted
hearts will be conducted in order to determine the following:
1. Evidence of CAV (coronary allograft vasculopathy)
2. Evidence of Endocardial fibroelastosis
3. Evidence of Rejection (acute and chronic)
4. Evidence of Myocardial infarction
5. Evidence of Fibrosis
6. Evidence of Fatty infiltration
A retrospective review of patient charts will also be utilized to compare the pathologic
findings to clinical data obtained prior to re-transplantation. The following information
will be collected:
1. Type of transplant method
2. Patient age at time of transplant
3. Echocardiographic Data including Tissue Doppler Imaging (if available)
4. Catheterization data
1. CAV as identified by coronary angiography
2. Ventricular end-diastolic pressure
3. Cardiac index
4. Ventricular ejection fraction
5. Clinical rejection history
;
Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT03663036 -
Arthroscopic Superior Capsular Reconstruction With Fascia Lata Autograft - Survivorship of the Autograft Analysis
|
N/A | |
Not yet recruiting |
NCT05855707 -
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
|
Phase 1 | |
Recruiting |
NCT04967391 -
Tumescence in HNC Skin Graft Reconstruction
|
Phase 3 | |
Recruiting |
NCT02061462 -
EVLP to Evaluate the Eligibility for Transplantation of DCD-Lungs
|
Phase 1 | |
Completed |
NCT01970605 -
Silver Graft All Comers Registry
|
||
Terminated |
NCT01564095 -
TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion
|
Phase 2/Phase 3 | |
Recruiting |
NCT04779957 -
Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy
|
Phase 2 | |
Terminated |
NCT04494061 -
A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
|
||
Terminated |
NCT04731298 -
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
|
Phase 2 | |
Completed |
NCT01848249 -
Deceased Donor Biomarkers and Recipient Outcomes
|
||
Active, not recruiting |
NCT02556879 -
Immunization Anti HLA in the Liver Transplant Recipients (DSATH)
|
N/A | |
No longer available |
NCT02026934 -
CliniMACS® CD34+ Reagent System for Expanded Access Use
|
N/A | |
Recruiting |
NCT00472329 -
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT04542954 -
Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
|
||
Recruiting |
NCT03717545 -
Second Transplantation for Graft Failure
|
N/A | |
Recruiting |
NCT03019809 -
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
|
Phase 2 | |
Recruiting |
NCT01631058 -
Renal Transplantation in the Elderly - nEverOld Study
|
Phase 4 | |
Completed |
NCT06340607 -
Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients
|
||
Not yet recruiting |
NCT04685174 -
Intraoperative NIRS of Transplanted Kidney for Prediction of Acute and Sub-acute Injury
|
Phase 3 |